Judges Scientific (JDG) AI Stock Analysis

• Market Cap: £371.13M
• Dividend Yield: 1.92%
• Average Volume (3M): 19.94K
• Price to Earnings (P/E): 33.7
• Beta (1Y): 0.41
• Revenue Growth: 5.46%
• EPS Growth: -26.44%
• Country: UK
• Employees: 767
• Sector: Technology
• Sector Strength: 88
• Industry: Hardware, Equipment & Parts
• EPS (TTM): 1.39
• Shares Outstanding: 6,651,052
• 10 Day Avg. Volume: 25,550
• 30 Day Avg. Volume: 19,941
• PEG Ratio: 7.16
• Price to Book (P/B): 6.45
• Price to Sales (P/S): 4.20
• P/FCF Ratio: 25.37
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: £7,640.00
• Price Target Upside: 33.57% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 64 Neutral
• Price Target: 5,871.00p ▲(2.64% Upside)

Judges Scientific demonstrates strong financial management, particularly in cash flow and profitability, which supports its stability. However, technical indicators suggest a bearish trend, and the stock appears overvalued based on its P/E ratio. These factors combine to yield a moderate overall stock score.

Positive Factors

Cash Generation

Strong cash generation supports operational flexibility and investment capacity, ensuring long-term financial stability and growth potential.

Diversified Revenue Model

A diversified revenue model with recurring income streams enhances resilience against market fluctuations and supports sustainable growth.

Balance Sheet Stability

A stable balance sheet with manageable leverage provides a solid foundation for future growth and reduces financial risk.

Negative Factors

Revenue Challenges

Recent revenue challenges could hinder growth momentum, requiring strategic adjustments to maintain market competitiveness.

Earnings Decline

A decline in earnings per share indicates potential profitability issues, which could impact investor confidence and future investment capacity.

Revenue Dip

A decline in revenue suggests potential market or operational challenges, necessitating strategic initiatives to restore growth.

Judges Scientific Business Overview & Revenue Model

Company Description

Judges Scientific (JDG) is a UK-based group dedicated to the design, manufacture, and sale of scientific instruments and equipment, primarily serving the research and industrial sectors. The company operates through various subsidiaries, focusing on niche markets that include materials testing, microscopy, and other specialized scientific applications. JDG's core products include advanced analytical instruments and laboratory equipment used in a range of fields such as pharmaceuticals, materials science, and education.

How the Company Makes Money

Judges Scientific generates revenue through the sale of its proprietary scientific instruments and equipment, as well as through ongoing maintenance and support services for these products. The company benefits from a diversified revenue model that includes direct sales to end-users, distribution partnerships, and potentially government contracts in research and development sectors. Key revenue streams include initial product sales, consumables, and service agreements, which provide recurring income. The company also engages in strategic acquisitions of niche technology firms, enhancing its product portfolio and market reach, thereby contributing to overall earnings growth.

Judges Scientific Financial Statement Overview

Summary

Judges Scientific exhibits strong financial management across all statements. The income statement reflects steady profitability, with some recent revenue challenges. The balance sheet is stable with manageable leverage, while the cash flow statement highlights excellent cash generation and liquidity. Continued focus on revenue growth and debt management could further enhance financial performance.

Income Statement

The company has shown solid gross profit margins, maintaining stable profitability over the years. The net profit margin is respectable, though there was a slight decline in revenue from 2023 to 2024. The EBIT and EBITDA margins are strong, indicating efficient operations. Overall, the income statement reflects a well-managed financial performance, but the recent revenue dip could be a concern.

Balance Sheet

The company's balance sheet shows a moderate debt-to-equity ratio, reflecting a balanced approach to leverage. The equity ratio indicates a solid foundation, though there is room for improvement in reducing liabilities. Return on equity is good, suggesting effective use of shareholder funds. The balance sheet is stable, but managing debt levels could enhance financial health further.

Cash Flow

The company demonstrates strong cash generation capabilities, with a positive operating cash flow to net income ratio. Free cash flow has grown steadily, indicating good financial management. The free cash flow to net income ratio supports a healthy cash conversion cycle, contributing to overall financial stability. The cash flow statement reflects robust liquidity and operational efficiency.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	143.00M	133.60M	136.10M	113.21M	91.29M	79.86M
Gross Profit	23.30M	92.00M	93.60M	21.01M	15.34M	10.02M
EBITDA	31.80M	30.90M	32.20M	29.00M	20.33M	15.17M
Net Income	11.00M	10.40M	9.50M	12.50M	12.68M	8.22M
Balance Sheet
Total Assets	200.30M	205.10M	183.50M	185.79M	88.98M	82.03M
Cash, Cash Equivalents and Short-Term Investments	18.90M	17.90M	13.70M	20.83M	18.41M	15.52M
Total Debt	69.30M	73.60M	65.30M	59.95M	21.32M	26.37M
Total Liabilities	107.60M	117.90M	100.90M	131.33M	45.58M	48.98M
Stockholders Equity	92.50M	86.90M	82.40M	54.24M	42.78M	32.19M
Cash Flow
Free Cash Flow	28.40M	22.10M	20.60M	12.33M	13.44M	10.53M
Operating Cash Flow	32.80M	28.50M	26.50M	20.22M	16.89M	11.79M
Investing Cash Flow	-18.70M	-22.60M	-25.90M	-50.80M	-5.21M	-12.67M
Financing Cash Flow	-300.00K	-1.40M	-7.60M	31.20M	-8.81M	2.34M

Judges Scientific Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 5720.00
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:JDG, the sentiment is Neutral. The current price of 5720 is above the 20-day moving average (MA) of 5116.00, above the 50-day MA of 5633.42, and below the 200-day MA of 6810.48, indicating a neutral trend. The MACD of -36.47 indicates Negative momentum. The RSI at 61.62 is Neutral, neither overbought nor oversold. The STOCH value of 88.86 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GB:JDG.

Judges Scientific Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RSW	69 Neutral	£2.53B	30.13	9.15%	2.12%	3.15%	-13.57%
DSCV	68 Neutral	£552.95M	22.56	8.49%	2.07%	0.49%	61.73%
JDG	64 Neutral	£371.13M	33.70	12.24%	1.92%	5.46%	-26.44%
SXS	63 Neutral	£4.08B	70.23	4.26%	2.04%	0.07%	-78.33%
Sector *	61 Neutral	$37.18B	12.37	-10.20%	1.83%	8.50%	-7.62%
GHH	56 Neutral	£155.04M	28.39	3.13%	2.58%	10.66%	21.19%
SOLI	55 Neutral	£81.00M	158.33	3.88%	1.75%	8.75%	-54.73%

Judges Scientific Corporate Events

Judges Scientific Executives Reinforce Commitment Through Share Purchases

Judges Scientific announced the purchase of ordinary shares by its Chief Financial Officer, Brad Ormsby, and Non-Executive Chairman, Ralph Elman, under an automatic dividend reinvestment program. This transaction, conducted on the London Stock Exchange’s AIM Market, reflects ongoing confidence in the company’s financial health and strategic direction, potentially strengthening its market position and signaling positive implications for stakeholders.

The most recent analyst rating on (GB:JDG) stock is a Hold with a £5699.00 price target. To see the full list of analyst forecasts on Judges Scientific stock, see the GB:JDG Stock Forecast page.

Judges Scientific Executives Participate in Share Incentive Plan

Judges Scientific plc announced the purchase of ordinary shares by the Trustees of the Share Incentive Plan, involving key executives including the CEO, CFO, COO, Group Business Development Director, and Group Commercial Director. This transaction, conducted on the London Stock Exchange’s AIM Market, reflects the company’s commitment to aligning management interests with shareholder value, potentially enhancing stakeholder confidence in the company’s strategic direction.

The most recent analyst rating on (GB:JDG) stock is a Hold with a £5699.00 price target. To see the full list of analyst forecasts on Judges Scientific stock, see the GB:JDG Stock Forecast page.

Judges Scientific Director Increases Stake in Company

Judges Scientific plc announced that Lushani Kodituwakku, a Non-Executive Director, along with closely associated persons, purchased a total of 1,766 ordinary shares of the company. This transaction increases Kodituwakku’s beneficial holding to 4,237 shares, representing approximately 0.06% of the company’s total issued share capital. This move reflects confidence in the company’s strategic direction and could potentially influence market perception positively.

The most recent analyst rating on (GB:JDG) stock is a Hold with a £6646.00 price target. To see the full list of analyst forecasts on Judges Scientific stock, see the GB:JDG Stock Forecast page.

Judges Scientific Executives Show Confidence with Share Purchases

Judges Scientific plc announced that several key executives, including the CEO, CFO, COO, Group Business Development Director, and Group Commercial Director, have purchased shares through the company’s Share Incentive Plan. These transactions, conducted on the London Stock Exchange’s AIM Market, reflect a unified confidence in the company’s future prospects and strategic direction, potentially strengthening stakeholder trust and market position.

The most recent analyst rating on (GB:JDG) stock is a Hold with a £6646.00 price target. To see the full list of analyst forecasts on Judges Scientific stock, see the GB:JDG Stock Forecast page.

Judges Scientific Announces Increase in Share Capital and Voting Rights

Judges Scientific has announced an increase in its total issued share capital to 6,649,452 Ordinary shares as of September 30, 2025. This change affects the total number of voting rights, which shareholders can use to determine their notifiable interest in the company under the Disclosure and Transparency Rules.

The most recent analyst rating on (GB:JDG) stock is a Hold with a £6646.00 price target. To see the full list of analyst forecasts on Judges Scientific stock, see the GB:JDG Stock Forecast page.

Judges Scientific Reports Robust Interim Results Amidst Challenging Market Conditions

Judges Scientific reported its interim results for the first half of 2025, showing a 15% increase in revenue to £70.2 million and a 17% rise in adjusted pre-tax profit to £12.6 million, despite a challenging trading environment. The company faced difficulties due to reduced US federal government research funding and trading challenges in certain businesses, but saw strong performance from Geotek and a recovery in China/Hong Kong. The interim dividend was increased by 10%, and the company remains focused on addressing trading challenges and supporting organic growth, while maintaining a solid order book and financial strength.

The most recent analyst rating on (GB:JDG) stock is a Hold with a £6202.00 price target. To see the full list of analyst forecasts on Judges Scientific stock, see the GB:JDG Stock Forecast page.

Judges Scientific Executives Participate in Share Incentive Plan

Judges Scientific plc announced the purchase of ordinary shares by the Trustees of the Share Incentive Plan, involving key executives including the CEO, CFO, COO, Group Business Development Director, and Group Commercial Director. The transactions, conducted on the London Stock Exchange’s AIM Market, reflect the company’s commitment to aligning management interests with shareholder value, potentially strengthening stakeholder confidence in the company’s strategic direction.

The most recent analyst rating on (GB:JDG) stock is a Hold with a £6202.00 price target. To see the full list of analyst forecasts on Judges Scientific stock, see the GB:JDG Stock Forecast page.